 |
市場調查報告書
商品編碼
1110126
耳鼻喉治療市場：按治療類型（設備、藥物類型）、器官類型、最終用戶、地區 - 規模、份額、前景、機會分析，2022-2030ENT Disorder Treatment Market, by Treatment Type (Devices and Drug Type ), by Organ Type, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 |
||||||
價格
簡介目錄
耳鼻喉科是治療與耳、鼻和喉有關的疾病的醫學分支。與耳、喉、鼻相關的疾病會顯著影響生活質量，一些如慢性扁桃體炎、耳部感染、嚴重的鼻竇炎問題，以及咽喉癌等病例可能會導致手術。為了治療這些疾病，需要在耳鼻喉科進行治療。這些疾病可以在設備和藥物的幫助下進行治療，但建議對重症患者進行手術。根據耳鼻喉科醫生的建議，在某些情況下需要進行手術，例如喉癌，但腫瘤科醫生建議切除腫瘤，然後進行放療或化療，具體取決於兩者的嚴重程度。按照步驟操作。
市場動態
主要參與者正專注於無機增長戰略，例如加強研究部門以及銷售和營銷方面的商業化交易和收購。例如，2017 年 7 月，Entellus Medical 宣布達成最終協議，收購 Spirox, Inc.，這是一家開發、製造和銷售可吸收鼻腔植入物和其他醫療設備的私營耳鼻喉科醫療技術公司。
此外，2021 年 8 月，全球醫療技術領導者美敦力與全球耳鼻喉科醫療技術領導者 Intersect ENT 簽訂協議，以改變患者護理方式，1 全現金收購 Intersect ENT 的所有股份以每股 28.25 美元的價格進行交易，企業價值約為 11 億日元。兩家公司的董事會已一致批准該交易。收購 Intersect ENT 將使美敦力能夠擴大其用於 ENT 手術的產品組合。我們產品組合的補充和美敦力的承諾將使我們能夠對患有慢性鼻竇炎 (CRS) 的患者產生積極影響。 Intersect ENT 的 PROPEL(R) 和 SINUVA(R) 鼻竇植入物是經過臨床驗證的解決方案，可打開鼻竇通道並施用抗炎類固醇以幫助癒合。將這些產品與美敦力的導航、動力儀器和現有的組織醫學產品相結合，將提供一套廣泛的解決方案，以幫助外科醫生治療 CRS 患者。
本研究的主要特點
- 本報告對全球耳鼻喉治療市場進行了深入分析，提供了以 2021 年為基準年的預測期（2022-2030 年）的市場規模和復合年增長率 (CAGR%)。
- 解釋不同細分市場的潛在收入機會，並描述該市場具有吸引力的投資建議矩陣。
- 該研究還提供了有關市場驅動因素、抑制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
- 基於公司亮點、產品組合、關鍵亮點、財務業績和戰略等參數的全球耳鼻喉治療市場主要參與者的概況。
- 本研究涵蓋的主要公司包括賽諾菲、阿斯利康、諾華公司、輝瑞公司、Mylan N.V.、梯瓦製藥工業有限公司、葛蘭素史克製藥、Otonomy Inc.、默克公司、Reddys 博士實驗室有限公司。 , Allergan plc, Cochlear Ltd., Sonova Holding AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S, Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone, Rexton Inc.、Avada Hearing Care、Miracle-Ear Inc.、MED-EL GmbH、Nuear Hearing Aids Inc.、Audiosync Inc.、Bernafon、American Hearing Systems Inc.、Unitron Hearing Inc. 和 Zounds Inc.
- 本報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
- 全球耳鼻喉治療市場報告迎合了該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和財務分析師。
- 利益相關者將能夠通過在分析全球耳鼻喉治療市場時使用的各種戰略矩陣來促進決策制定。
內容
第 1 章目的和先決條件
- 調查目的
- 先決條件
- 縮寫說明
第2章市場展望
- 舉報內容
- 市場定義和範圍
- 執行摘要
- 市場快照：按治療類型
- 市場快照：按器官類型
- 市場快照：按最終用戶分類
- 市場概況：按地區劃分
- 連貫的機會圖 (COM)
第 3 章市場動態、監管和趨勢分析
- 市場動態
- 驅動程序
- 約束因素
- 市場機會
- 主要亮點
- 保險報銷場景
- 技術進步
- 最近獲得 FDA 批准
- 監管場景
- PEST 分析
- 流行病學
第 4 章全球耳鼻喉疾病治療市場 - 冠狀病毒 (COVID-19) 大流行的影響
- 整體影響
- 政府舉措
- COVID-19 對市場的影響
第 5 章全球耳鼻喉治療市場，按治療類型，2017-2030 年
- 按設備
- 助聽器
- 人工聲帶（語音假體
- 鼻夾板
- 聽力植入物
- 其他
- 2017-2030 年市場規模、預測、同比增長率
- 抗生素
- 抗組胺藥
- 類固醇
- 抗炎藥
- 其他
第 6 章按器官類型分列的全球耳鼻喉治療市場：2017-2030
- 耳朵
- 鼻子
- 喉嚨
第 7 章全球耳鼻喉治療市場：按最終用戶，2017-2030 年
- 醫院
- 醫務室
- 門診手術中心
- 家庭保健設施
- 其他
第 8 章全球耳鼻喉治療市場：按地區分列，2017-2030 年
- 北美
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲地區
- 歐洲
- 英國
- 德國
- 意大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- 東盟
- 澳大利亞
- 韓國
- 其他亞太地區
- 中東
- 海合會
- 以色列
- 其他中東地區
- 非洲
- 北非
- 中非
- 南非
第 9 章競爭格局
- 熱圖分析
- 市場份額分析
- 公司簡介
- Sanofi
- AstraZeneca Plc
- Novartis AG
- Pfizer, Inc.
- Mylan N.V.
- Teva Pharmceutical Industries Ltd.
- GlaxoSmithKline Plc
- Otonomy, Inc.
- Merck & Co., Inc.
- Dr. Reddy's Laboratories Ltd.
- Allergen Plc
- Cochlear Ltd.
- Sonova Holdings AG.
- Siemens Healthineers
- Starkey Laboratories, Inc.
- William Demant Holdings, A/S
- Widex A/S
- GN Re/Sound A/S
- Sonic Innovations. Inc.
- Panasonic Corporation
- Beltone
- Rexton Inc.
- Avada Hearing Care
- Miracle-Ear., Inc.
- MED-EL GmBH
- Nuear Hearing Aids, Inc.
- AudioSync, Inc.
- Bernafon
- American Hearing Systems, Inc.
- Unitron Hearing, Inc.
- Zounds, Inc.
第10章 章節
- 參考文獻
- 調查手法介紹
簡介目錄
Product Code: CMI1326
ENT also known as otolaryngology is a stream of medical science that deals with disorders associated with ear, nose, and throat. Diseases related to ears, throat, and nose significantly affect the quality of life and could lead to surgeries in few cases such as chronic tonsillitis, ear infections, and severe sinusitis problems as well as cancers of the throat or larynx, and others. In order to treat these disorders, ENT treatment is required. These diseases can either be treated with the help of devices or drugs, however, surgeries are recommended to patients with severe cases. Surgical procedures are required in few cases such as throat cancer as recommended by otolaryngologist, however, an oncologist performs the tumor removal procedures, which is either followed by a radiation or chemotherapy, depending on the severity.
Market Dynamics
Key players are focusing on inorganic growth strategies such as agreement and acquisitions for enhancement of research department as well as commercialization of products in terms of sales and marketing. For instance, in July 2017, Entellus Medical announced a definitive agreement to acquire Spirox, Inc. a privately held ENT medical technology that develops, manufactures and markets absorbable nasal implants and other medical devices.
Moreover, in August 2021, Medtronic plc., the global leader in medical technology signed agreement with Intersect ENT, a global ear, nose, and throat (ENT) medical technology leader dedicated to transforming patient care, in which Medtronic acquired all shares of Intersect ENT for US$28.25 per share in an all-cash transaction implying an enterprise value of approximately US$1.1 billion. The boards of directors of both companies have unanimously approved the transaction. Medtronic's acquisition of Intersect ENT expands the company's portfolio of products used during ear, nose, and throat procedures. The complementary product lines and Medtronic's efforts to have a positive impact for patients who suffer from chronic rhinosinusitis (CRS). Intersect ENT's PROPEL® and SINUVA® sinus implants are clinically proven solutions that open sinus passageways and deliver an anti-inflammatory steroid to aid in healing. By combining these products with Medtronic's navigation, powered instruments, and existing tissue health products, the company intends to offer a broader suite of solutions to assist surgeons treating CRS patients.
Key features of the study:
- This report provides an in-depth analysis of the global ENT disorder treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ENT disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Sanofi, AstraZeneca, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc., Merck & Co., Dr. Reddys Laboratories Ltd., Allergan plc, Cochlear Ltd., Sonova Holding AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S, Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone, Rexton Inc., Avada Hearing Care, Miracle-Ear Inc., MED-EL GmbH, Nuear Hearing Aids Inc., Audiosync Inc., Bernafon, American Hearing Systems Inc., Unitron Hearing Inc., and Zounds Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global ENT disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ENT disorder treatment market
Detailed Segmentation:
- Global ENT Disorder Treatment Market, By Treatment Type:
- By Devices
- Hearing Aid Devices
- Voice Prostheses
- Nasal Splints
- Hearing Implants
- Others
- By Drugs
- Antibiotics
- Antihistamines
- Steroids
- Anti-inflammatory Drugs
- Others
- By Devices
- Global ENT Disorder Treatment Market, By Organ Type:
- Ears
- Nose
- Throat
- Global ENT Disorder Treatment Market, By End User:
- Hospital
- Clinics
- Ambulatory Surgical Centers
- Home Care Settings
- Others
- Global ENT Disorder Treatment Market, By Region:
- North America
- By Country
- U.S.
- Canada
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- Sanofi *
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca Plc
- Novartis AG
- Pfizer, Inc.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline Plc
- Otonomy, Inc.
- Merck & Co., Inc.
- Reddy's Laboratories Ltd.
- Allergen Plc
- Cochlear, Ltd.
- Sonova Holdings AG
- Siemens Healthineers
- Starkey Laboratories, Inc.
- William Demant Holdings A/S
- Widex A/S
- GN ReSound A/S
- Sonic Innovations, Inc.
- Panasonic Corporation
- Beltone
- Rexton, Inc.
- Avada Hearing Care
- Miracle-Ear, Inc.
- MED-EL GmbH
- Nuear Hearing Aids Inc.
- AudioSync, Inc.
- Bernafon
- American Hearing Systems, Inc.
- Unitron Hearing, Inc.
- Zounds, Inc.
- Sanofi *
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Organ Type
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Key Highlights
- Reimbursement Scenario
- Technological Advancements
- Recent FDA Approvals
- Regulatory Scenario
- PEST Analysis
- Epidemiology
4. Global ENT Disorder Treatment Market- Impact of Coronavirus (Covid-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
5. Global ENT Disorder Treatment Market, By Treatment Type, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- By Devices
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Hearing Aid Devices
- Voice Prostheses
- Nasal Splints
- Hearing Implants
- Others
- By Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Segment Trends
- Antibiotics
- Antihistamines
- Steroids
- Anti-inflammatory Drugs
- Others
6. Global ENT Disorder Treatment Market, By Organ Type, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Ears
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Nose
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Throat
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
7. Global ENT Disorder Treatment Market, By End User, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Hospitals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Ambulatory Surgical Centers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Home Care Settings
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
8. Global ENT Disorder Treatment Market, By Region, 2017 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Organ Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Organ Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Organ Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Organ Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Organ Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Organ Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profiles
- Sanofi*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- AstraZeneca Plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Mylan N.V.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Teva Pharmceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- GlaxoSmithKline Plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Otonomy, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Allergen Plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Cochlear Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Sonova Holdings AG.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Siemens Healthineers
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Starkey Laboratories, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- William Demant Holdings, A/S
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Widex A/S
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- GN Re/Sound A/S
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Sonic Innovations. Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Panasonic Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Beltone
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Rexton Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Avada Hearing Care
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Miracle-Ear., Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- MED-EL GmBH
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Nuear Hearing Aids, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- AudioSync, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Bernafon
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- American Hearing Systems, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Unitron Hearing, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Zounds, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Analyst Views
10. Section
- References
- Research Methodology
- About Us and Sales Contact
